Skip to search formSkip to main contentSkip to account menu

CGP 57148

Known as: CGP-57148, CGP57148, CGP57148B 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Imatinib mesylateimatinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2011
Review
2011
Recent developments in drug resistance mechanism in chronic myeloid leukemia: a review
A revolution in medical science was marked with the advent of imatinib, a site‐specific drug for the management of patients with… 
Review
2005
Review
2005
Imatinib Mesylate: Targeted Therapy of Gastrointestinal Stromal Tumor
The clinical application of tyrosine kinase inhibitors for cancer treatment represents a therapeutic breakthrough. The rationale… 
2003
2003
L’imatinib mésylate: une révolution dans le traitement de la leucémie myéloïde chronique
667 M/S n° 6-7, vol. 19, juin-juillet 2003 > La leucémie myéloïde chronique (LMC) est une affection maligne clonale de la cellule… 
Review
2001
Review
2001
[Leukemogenesis and new therapy development: the example of chronic myelogenous leukemia].
During the past ten years, the improvements of our understanding of cellular signal transduction pathways provide new targets for… 
2000
2000
Growth inhibition of Ph+ progenitor cells from CML patients using the tyrosine kinase inhibitor CGP57148B.
BACKGROUND Different methods have been investigated for their purging capacity of contaminating CML cells in autologous stem cell… 
2000
2000
The Tyrosine Kinase Inhibitor CGP 57148 ( ST 1 571 ) Induces Apoptosis in BCR-ABL-positive Cells by Down-Regulating BCL-X 1
CGP 57148 is a potent inhibitor of the ABL protein tyrosine kinase and a promising new compound for the treatment of a variety of… 
2000
2000
[beta1 Integrin Dysfunction in Adult Chronic Myeloid Leukemia Bone Marrow Cells]
According to our previous experiments, Ph(+) chronic myeloid leukemia (CML) cell line K562 cells have defects in beta 1 integrin… 
1999
1999
Favorable therapeutic index of a p210BCR-ABL-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors
Purpose: In order to assess the effect of the tyrosine kinase inhibitor CGP57148B on lineage-committed and primitive chronic… 
1999
1999
Induces Hematologic Malignancies in Mice That Respond to a Specific Tyrosine Kinase Inhibitor
The TEL/PDGFbR fusion protein is expressed as the consequence of a recurring t(5;12) translocation associated with chronic… 
1998
1998
Protein tyrosine phosphatase PTP 1 B suppresses p 210 bcr-abl-induced transformation of Rat-1 fibroblasts and promotes differentiation of K 562 cells
The bcr-abl chimeric oncoprotein exhibits deregulated protein tyrosine kinase activity and is implicated in the pathogenesis of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)